The advancement of immunoassays designed for the detection of N-terminal cleaved-tau fragments holds the potential to serve as a diagnostic tool for Alzheimer’s disease (AD) and distinguish it from other tauopathies [75, 78]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.